Literature DB >> 17964780

Synthesis and in vivo activity of MK2 and MK2 substrate-selective p38alpha(MAPK) inhibitors in Werner syndrome cells.

Terence Davis1, Mark C Bagley, Matthew C Dix, Paola G S Murziani, Michal J Rokicki, Caroline S Widdowson, Jameel M Zayed, Marcus A Bachler, David Kipling.   

Abstract

A benzopyranopyridine inhibitor of mitogen-activated protein kinase-activated protein kinase 2 (MK2) is prepared rapidly and efficiently in one step using microwave dielectric heating, whereas a substrate-selective p38 MAPK inhibitor was prepared using conventional heating techniques. The former had MK2 inhibitory activity above 2.5 microM concentration, whereas the latter showed no MK2 inhibition at 10 microM. However, rather than rescuing the reduced cellular growth rate and aged morphology of hTERT-immortalised WS dermal fibroblasts, both induce a state resembling stress-induced cellular senescence, suggesting that these inhibitors may have limited therapeutic use.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17964780     DOI: 10.1016/j.bmcl.2007.10.036

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  11 in total

1.  Discovery and Characterization of a Biologically Active Non-ATP-Competitive p38 MAP Kinase Inhibitor.

Authors:  Brice A P Wilson; Muhammad S Alam; Tad Guszczynski; Michal Jakob; Shilpa R Shenoy; Carter A Mitchell; Ekaterina I Goncharova; Jason R Evans; Peter Wipf; Gang Liu; Jonathan D Ashwell; Barry R O'Keefe
Journal:  J Biomol Screen       Date:  2015-11-04

2.  Are senescence and exhaustion intertwined or unrelated processes that compromise immunity?

Authors:  Arne N Akbar; Sian M Henson
Journal:  Nat Rev Immunol       Date:  2011-04       Impact factor: 53.106

3.  Inhibition of the protein kinase MK-2 protects podocytes from nephrotic syndrome-related injury.

Authors:  Ruma Pengal; Adam J Guess; Shipra Agrawal; Joshua Manley; Richard F Ransom; Robert J Mourey; Rainer Benndorf; William E Smoyer
Journal:  Am J Physiol Renal Physiol       Date:  2011-05-25

4.  A fluorescence-based assay for p38α recruitment site binders: identification of rooperol as a novel p38α kinase inhibitor.

Authors:  Jing Li; Tamer S Kaoud; Jake LeVieux; Brad Gilbreath; Swapna Moharana; Kevin N Dalby; Sean M Kerwin
Journal:  Chembiochem       Date:  2012-12-06       Impact factor: 3.164

Review 5.  Targeting Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (MAPKAPK2, MK2): Medicinal Chemistry Efforts To Lead Small Molecule Inhibitors to Clinical Trials.

Authors:  Mario Fiore; Stefano Forli; Fabrizio Manetti
Journal:  J Med Chem       Date:  2015-11-09       Impact factor: 7.446

6.  Distinct roles of MK2 and MK5 in cAMP/PKA- and stress/p38MAPK-induced heat shock protein 27 phosphorylation.

Authors:  Alexey Shiryaev; Gianina Dumitriu; Ugo Moens
Journal:  J Mol Signal       Date:  2011-05-16

7.  Microwave-Assisted Synthesis of a MK2 Inhibitor by Suzuki-Miyaura Coupling for Study in Werner Syndrome Cells.

Authors:  Mark C Bagley; Mohammed Baashen; Irina Chuckowree; Jessica E Dwyer; David Kipling; Terence Davis
Journal:  Pharmaceuticals (Basel)       Date:  2015-06-03

Review 8.  Use of p38 MAPK Inhibitors for the Treatment of Werner Syndrome.

Authors:  Mark C Bagley; Terence Davis; Paola G S Murziani; Caroline S Widdowson; David Kipling
Journal:  Pharmaceuticals (Basel)       Date:  2010-06-04

9.  The effect of small-molecule inhibition of MAPKAPK2 on cell ageing phenotypes of fibroblasts from human Werner syndrome.

Authors:  Terence Davis; Michal J Rokicki; Mark C Bagley; David Kipling
Journal:  Chem Cent J       Date:  2013-01-29       Impact factor: 4.215

Review 10.  Senescent T cells within suppressive tumor microenvironments: emerging target for tumor immunotherapy.

Authors:  Xia Liu; Daniel F Hoft; Guangyong Peng
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.